Encouragingly, Rimegepant, a small-molecule CGRP receptor antagonist used to treat migraines, and SQ22536, an adenylate cyclase inhibitor which effectively inhibits the production of intracellular cAMP and suppresses the activation of the cAMP pathway, could reduce the elevated levels of KLF2 induced by CGRP and offset CGRP’s detrimental impact on DC development (Fig. 5C, D and Supplementary Fig. 5F). Here, KLF2 is linked to migraine disorder.